Core Insights - Captain T Cell GmbH has been selected for residency in the Bayer Co.Lab incubator in Berlin, which supports biotech and life science innovators [1][2] - The company is developing next-generation TCR-based cell therapies for solid tumors, with a focus on both autologous and allogeneic product candidates [3][5] Company Overview - Captain T Cell is advancing a proprietary TCR-T cell therapy platform, with its lead program, CTC 127, showing best-in-class in vivo efficacy in preclinical models [3] - The first-in-human clinical study for CTC 127 is set to begin in 2027, while the allogeneic platform has recently achieved promising pre-clinical results [3] Bayer Co.Lab Overview - Bayer Co.Lab provides access to state-of-the-art lab and office infrastructure, global expertise, and a broader life science ecosystem to support innovative biotech companies [2][6] - The incubator is part of Bayer's global network aimed at accelerating breakthrough technologies in healthcare [2][6] Recognition and Community - Captain T Cell won first place for "Biggest Scientific Breakthrough" at the Grand Opening of Bayer Co.Lab Berlin, highlighting its innovative potential [4] - The company joins a cluster of high-potential life science ventures in a dynamic innovation hub for oncology and advanced therapeutics [4]
Captain T Cell Joins Bayer Co.Lab Berlin to Accelerate Autologous and Allogeneic TCR-T Cell Therapy Programs for Cancer Patients